Recent progress in high-resolution mass spectrometry (HRMS) and liquid chromatography–mass spectrometry (LC–MS) methods for the structural characterization of brentuximab vedotin and trastuzumab emtansine are presented.
Sarah Cianferani
Advertisement
Articles by Sarah Cianferani
Advertisement
Latest Updated Articles
Harnessing the Benefits of Mass Spectrometry for In-depth Antibody Drug Conjugates Analytical CharacterizationPublished: October 2nd 2015 | Updated:
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Advancing RNA-Based Therapeutics: IQ Consortium Experts on Optimizing Chromatographic Bioanalysis
5
